ProMetic Life Sciences’s lead product for the treatment of idiopathic pulmonary fibrosis (IPF), called PBI-4050, is going to be tested in a Phase 2/3 clinical trial. Supported by efficacy data from a Phase 2 study (NCT02538536), the U.S. Food and Drug Administration (FDA) has accepted the…
Bristol-Myers Squibb and Nordic Bioscience will collaborate on the development of biomarkers that can help diagnose and keep tabs on the status of fibrotic diseases like pulmonary fibrosis (PF). A biomarker is a molecule that can be used to diagnose a disease or predict its progression by…
Esbriet (pirfenidone) was as effective as prednisone and better than acetylcysteine at inhibiting inflammation and fibrosis in the lungs of rats with idiopathic pulmonary fibrosis (IPF), according to a study. The research, “Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models,” was…
NuMedii, a company that applies computer-based artificial intelligence (AI) to medical analysis, has teamed up with Three Lakes Partners, a Chicago-based investment and philanthropic organization, to develop drugs to treat idiopathic pulmonary fibrosis (IPF). Pulmonary fibrosis is a lung disorder that involves scarring of the lungs, leading to serious breathing…
A new imaging strategy shows promising results in improving the diagnosis and treatment of people with pulmonary fibrosis (PF). The study, “Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models,” appeared in the journal Science Translational Medicine. Scientists at Massachusetts General Hospital (MGH) have developed…
Esbriet (pirfenidone) can prolong idiopathic pulmonary fibrosis (IPF) patients’ survival, according to a review of clinical trials covering the anti-inflammatory and anti-fibrotic agent. Researchers also said that Esbriet is safe, but does not help every IPF patient. The study, “Role of pirfenidone in the management of pulmonary fibrosis,”…
The France Foundation will be working together with the Pulmonary Fibrosis Foundation to expand its educational resources on major interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF). According to a press release provided by the France Foundation to Pulmonary Fibrosis News, the collaboration will provide education…
Among the various ways to conserve your energy throughout the day when you have idiopathic pulmonary fibrosis, I’ve found the most necessary way for me is to take naps. These help me function throughout my day. They are now absolutely crucial for me when I have an evening social event planned after a…
An antibody that protects against radiation-induced lung fibrosis could improve the treatment of cancers that stem from radiation damage to the lungs, according to a study. The research demonstrated that an antibody against connective tissue growth factor, or CTGF, prevented pulmonary fibrosis in up to 80 percent of irradiated mice. Those…
Researchers in Finland have identified a protein called AMPK as a possible new target for therapies aimed to treat pulmonary fibrosis and other fibrotic diseases. Their study, “AMPK Negatively Regulates Tensin-Dependent Integrin Activity,” appeared in The Journal of Cell Biology. In human tissues, the space between adjacent cells, called…
Get regular updates to your inbox.
